Grants for Independent School Districts

This grant provides funding for researchers to conduct early-stage clinical trials aimed at improving treatments for patients with arthritis, musculoskeletal, or skin diseases.

This funding opportunity supports innovative research projects that explore the effective use and sharing of genomic information in clinical care for diverse populations, regardless of their racial, ethnic, or socioeconomic backgrounds.

This funding opportunity provides financial support for researchers to explore innovative ways to integrate genomic information into clinical care, particularly focusing on diverse and underserved populations to improve health equity.

The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

This funding opportunity supports innovative research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and underrepresented populations, while addressing health disparities and enhancing the integration of genomic medicine into healthcare practices.

Online Resources for Starting Businesses. Economic inclusion describes the efforts made to bring DBEs into the economic mainstream. For the purposes of BERO, DBE refers to businesses owned by women, minorities, veterans and persons with disabilities; as well as those in areas of chronic high unemployment and low income. BERO was legislatively established within the Department of Economic and Community Development in 1977 by Title 4, Chapter 26 as the office of business enterprise. Serves as a voice for and advocate of economic inclusion; Analyzes, disseminates, and promotes best practices and access to capital to service providers; and Reports on the status of DBEs statewide (disadvantaged businesses).

This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

This grant provides funding to neuroscience researchers to advance their small molecule drug discovery and development projects aimed at treating disorders of the nervous system.

The purpose of the grant is to provide academic instruction and education services below the postsecondary level. Services include Adult Basic Education, Adult Secondary Education, English as a Second Language and Corrections Education. Adult Education, as part of the Workforce Innovations and Opportunity Act (WIOA), provides services to adults to build the knowledge and skills necessary for high school equivalency (HiSET), employment, post-secondary opportunities, and economic self-sustainability.

This funding opportunity supports researchers developing innovative technologies to enhance the delivery of treatments for HIV and substance use disorders, focusing on improving patient outcomes and understanding the effects of addictive substances.

The National Cancer Institute is offering funding for research projects aimed at validating the effectiveness of various markers and assays in cancer detection, diagnosis, treatment, and prevention, with a focus on developing these into clinical assays and ensuring their performance across multiple laboratories.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) Courses for Skills Development; and (2) Develop and implement a program to prepare nurse scientists, and scientists in aligned fields, to conduct research on the social determinants of health in alignment with the NINR Strategic Plan.

This funding opportunity supports U.S.-based researchers and organizations in developing non-addictive pain relief therapies to combat the opioid crisis, with a focus on advancing preclinical candidates toward clinical trials.

This grant provides funding for research on how HIV and substance use affect placental health and maternal outcomes, targeting a wide range of institutions and researchers focused on these critical health issues.

This funding opportunity provides financial support for small-scale research projects that investigate the ethical, legal, and social challenges arising from advancements in human genetic and genomic research.

This funding opportunity supports research on the ethical, legal, and social implications of human genetics and genomics, particularly focusing on diverse perspectives and community engagement.

This funding opportunity supports researchers exploring the ethical, legal, and social issues related to human genetic and genomic research, particularly as these technologies become more integrated into healthcare and society.

The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids.Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.

The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Proposals investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.

This funding opportunity supports clinical trials aimed at developing and testing new treatments for communication disorders, such as those affecting hearing and speech, with a focus on ensuring they can be integrated into standard medical care.